Inspira Technologies Launches Innovative Disposable Kit
Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN), a pioneer in respiratory support technology, has announced an ambitious development project aimed at revolutionizing perfusion systems. This new disposable kit is designed specifically for the perfusion market, marking a significant step in their strategy to generate recurring revenues through products intended to work alongside the INSPIRA ART100 system.
Enhancing Patient Monitoring with Cutting-Edge Design
The innovative disposable kit is constructed as a single-use product that will identify and alert medical staff to any performance changes during operation. This unique design is set to deliver a seamless experience for medical teams, ultimately enhancing product safety and boosting patient protection, which is critical in fast-paced healthcare environments.
FDA Clearance on the Horizon
Inspira Technologies plans to seek U.S. Food and Drug Administration (FDA) clearance for marketing the disposable kit. Once approved, the kit will be made available to medical facilities utilizing the INSPIRA ART100 system. This system has already made significant strides, receiving FDA 510(k) clearance for Cardiopulmonary Bypass (CPB) procedures and Israeli medical device certification for extra-corporeal membrane oxygenation. Remarkably, the deployment of the first manufactured devices is anticipated by late 2024, offering a new tool for healthcare providers.
A Statement from Leadership
Mr. Dagi Ben-Noon, co-founder and CEO of Inspira Technologies, expressed enthusiasm about the new kit, stating, "This innovation reflects Inspira's commitment to enhancing patient care through advanced technology. We believe this disposable kit will elevate safety and improve the user experience for medical professionals in critical situations."
Transforming Mechanical Ventilation with INSPIRA ART
Inspira Technologies is at the forefront of medical innovation with its groundbreaking Augmented Respiration Technology (INSPIRA ART), setting the stage for a revolution in the $19 billion mechanical ventilation market. Designed to assist approximately 20 million ICU patients with acute respiratory failure annually, the INSPIRA ART presents a vital alternative that enables patients to maintain stable oxygen levels without the discomfort of traditional ventilators, keeping them awake and responsive during treatment.
Real-Time Monitoring Capabilities
A highlight of the INSPIRA ART system is the clip-on HYLA blood sensor, which offers real-time continuous blood monitoring. This innovative technology alerts physicians to changes in a patient’s condition without the need for frequent blood sampling, thus streamlining patient care and allowing healthcare providers to make informed decisions swiftly and efficiently.
Ongoing Innovations and Future Developments
The journey for Inspira Technologies does not end here. The company is actively developing other products and technologies, including the INSPIRA ART500, the portable modular device known as Cardi-ART, the VORTX orbiting oxygen delivery system, and the HYLA blood sensor. These technologies are currently in the design and development phase and will undergo further testing to pave the way for future market launches.
Contact for More Information
For more details about Inspira Technologies and its pioneering advancements in medical technology, potential investors and partners are encouraged to connect through the company’s media relations. They can be reached via email at info@inspirao2.com or by phone at +972-9-9664485.
Frequently Asked Questions
What is the focus of the new disposable kit from Inspira Technologies?
The new disposable kit is intended for the perfusion market, designed to enhance performance monitoring and improve patient safety during treatment.
When is the disposable kit expected to be available?
The kit is expected to be deployed in U.S. medical facilities by the end of 2024, pending FDA clearance.
What technologies does the INSPIRA ART use?
The INSPIRA ART utilizes Augmented Respiration Technology, which stabilizes oxygen saturation levels in patients without traditional ventilators.
How does the HYLA blood sensor benefit patients?
The HYLA blood sensor provides real-time monitoring, allowing healthcare providers to track patient conditions without the need for frequent blood draws.
Who is the CEO of Inspira Technologies?
Mr. Dagi Ben-Noon serves as the co-founder and CEO of Inspira Technologies, guiding the company’s innovative strategies.
